Skip to content
Vineet Laboratories logo

Vineet Laboratories

VINEETLAB NSE
₹36.06 0.73 (1.98%)
Market Cap
₹69.26 Cr
P/E
62.17

Vineet Laboratories (VINEETLAB) share price was ₹36.06 at the 28 Oct 2026 close; market capitalisation ₹69.26 Cr; P/E (TTM) 62.17; sector Healthcare. The share price fell 4.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue rose 34.2% year on year to ₹18.89 Cr and net profit was ₹0.73 Cr, against −₹10.53 Cr a year earlier (compared with Mar 2025). Promoters held 5.98% of Vineet Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 37/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹36.06 −1.81 −4.78% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹69.26 Cr
P/E (TTM)
62.17
EBITDA
₹8.48 Cr
Return on Equity
-137.85%
Debt to Equity
0.99
Book Value
₹23.75
EPS (TTM)
₹0.58
52W High
₹43.50
52W Low
₹27.96

Price-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Vineet Laboratories (this company)
₹36.0662.1769 Cr1.522.72%-137.85%-83.36%63 Cr1 Cr
Median 8 companies₹1,561.5548.521,17,574 Cr4.690.72%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
37 Weak
Overall score
Data confidence 100/100

Category scores

Quality Poor 25
Returns, margins, earnings quality 22%
Valuation Weak 40
Cheap vs sector & own history 24%
Growth Poor 14
Sales & profit trajectory 9%
Financial Health Poor 25
Solvency, leverage, coverage 9%
Momentum Good 55
Trend strength, vol-adjusted 12%
Ownership Weak 45
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

6
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -24.6% over past five years.
  • Promoter holding is low: 5.98%
  • Company has a low return on equity of -22.7% over last 3 years.
  • Promoter holding has decreased over last 3 years: -32.7%
  • Working capital days have increased from 26.7 days to 89.0 days

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

BearishNeutralBullish

Bearish

Bearish
10
Neutral
6
Bullish
3

Moving Averages

BearishNeutralBullish

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
-22.86% higher than 3Y

change over 1 year

Net Income Growth
-106% lower than 3Y

change over 1 year

Cash Flow Change
274%

change over 1 year

EBITDA Margin Change
-177%

change over 1 year Operating margin 13.18% · Mar 2026

Quarterly Results

Particulars Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
57.2
37.52
43.37
32.65
37.05
23.86
18.96
18.1
14.08
7.44
17.42
15.65
18.89
Expenses
51.39
37.26
39.2
33.29
33.63
24.65
19.27
22.23
25.12
7.13
14.24
13.17
16.4
Operating Profit
5.81
0.26
4.17
-0.64
3.42
-0.79
-0.31
-4.13
-11.04
0.31
3.18
2.48
2.49
OPM %
10.16%
0.69%
9.61%
-1.96%
9.23%
-3.31%
-1.64%
-22.82%
-78.41%
4.17%
18.25%
15.85%
13.18%
Other Income
0.03
0.03
0.01
0.01
0.41
0.37
0.2
0.03
1.38
0.02
0.01
0.05
0.03
Interest
0.37
0.96
1.02
1.08
1.72
1.14
0.99
0.95
0.9
0.61
2.19
1.09
0.99
Depreciation
0.62
0.61
0.61
0.63
0.67
0.61
0.62
0.62
0.66
0.63
0.63
0.63
0.54
PBT
4.85
-1.28
2.55
-2.34
1.44
-2.17
-1.72
-5.67
-11.22
-0.91
0.37
0.81
0.99
Tax %
26.8%
-2.34%
4.71%
-11.11%
-34.03%
-1.84%
6.98%
0.53%
-6.24%
-4.4%
-8.11%
-3.7%
27.27%
Net Profit
3.55
-1.25
2.42
-2.07
1.92
-2.13
-1.83
-5.71
-10.53
-0.87
0.4
0.85
0.73
EPS (₹)
1.85
-0.65
1.26
-1.08
1
-1.11
-0.95
-2.97
-5.48
-0.45
0.21
0.44
0.38
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
0
243
191
212
151
75
59.4
Expenses
0.01
235
178
205
143
91.28
50.91
Operating Profit
-0.01
8.15
13.16
7.66
7.2
-16.28
8.49
OPM %
—
3.35%
6.89%
3.61%
4.78%
-21.71%
14.29%
Other Income
0
0.39
0.29
0.12
0.46
1.99
0.1
Interest
0
2.67
2.09
3.38
4.78
3.98
4.89
Depreciation
0
1.81
2.02
2.37
2.52
2.5
2.41
PBT
-0.01
4.06
9.34
2.03
0.36
-20.77
1.29
Tax %
0%
56.16%
28.91%
38.42%
-183.33%
-2.79%
13.18%
Net Profit
-0.01
1.78
6.64
1.25
1.03
-20.19
1.11
EPS (₹)
-0.11
0.93
3.46
0.65
0.54
-10.52
0.58
Div. Payout %
0%
0%
13.89%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.41
9.22
9.22
9.22
9.22
9.22
19.21
Reserves
-0.01
17.4
24
24.46
25.51
5.43
26.4
Borrowings
0
12.48
26.51
31.09
44.3
40.05
45.33
Other Liabilities
0
69.64
73.59
51.08
37.84
39.84
33.84
Total Liabilities
0.4
109
133
116
117
94.54
125
Fixed Assets
0
19.67
21.38
26.65
26.92
25.46
24.24
CWIP
0
0
0
0
0
0
0
Investments
0
0.12
0.14
0.13
0.18
0.21
0.19
Other Assets
0.4
88.95
112
89.07
89.77
68.87
100
Total Assets
0.4
109
133
116
117
94.54
125
Figures in ₹ Crores

Cash Flow

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
27.49
7.63
-9.62
-6.61
11.49
-12.03
Investing
0
-7.81
-3.68
-6.69
-2.22
-3.18
-1.11
Financing
0
18.62
11.96
0.27
8.43
-8.23
29.74
Net Cash Flow
0
38.3
15.91
-16.03
-0.4
0.08
16.6
Free Cash Flow
0
27.49
7.63
-17.25
-9.4
10.44
-13.23
CFO/OP
0
327
82
-87
-88
-71
-144
Figures in ₹ Crores

Ratios

Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
64.03
69.14
60.45
76.59
64.48
70.05
Inventory Days
—
73.12
109
97.79
158
260
606
Days Payable
—
114
161
73.9
103
175
240
Cash Conversion Cycle
—
23.07
17.13
84.34
131
150
437
Working Capital Days
—
14.41
-19.46
20.63
28.48
-37.28
88.98
ROCE %
—
34.08%
23.13%
8.69%
6.65%
-27.95%
8.49%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vineet Laboratories insights

63 extracted metrics + investor summaries across FY20–FY26.

Shareholding Pattern

FIIs0.24%Public80.61%Promot.5.98%Others13.17%As ofSep 2026

Documents

Frequently Asked Questions about Vineet Laboratories

What does Vineet Laboratories Ltd do?
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
Where is Vineet Laboratories Ltd (VINEETLAB) listed?
Vineet Laboratories Ltd trades as VINEETLAB on the NSE and under code 543298 on the BSE.
Which sector does Vineet Laboratories Ltd belong to?
Vineet Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Vineet Laboratories Ltd?
Vineet Laboratories Ltd has a market capitalisation of ₹69.26 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Vineet Laboratories Ltd?
Vineet Laboratories Ltd trades at a PE ratio of 62.17 as of 28 Oct 2026, on earnings per share of ₹0.58, against a book value of ₹23.75 per share.
What is the 52-week high and low of Vineet Laboratories Ltd?
Over the last 52 weeks Vineet Laboratories Ltd has traded between ₹27.96 and ₹43.5 as of 28 Oct 2026.
Does Vineet Laboratories Ltd pay dividends?
Vineet Laboratories Ltd has a dividend yield of 2.72%.
What is the Return on Equity (ROE) of Vineet Laboratories Ltd?
Vineet Laboratories Ltd reported a return on equity of -137.85%. Its debt-to-equity ratio is 0.99.

Company Information

Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs

Website vineetlabs.co.in
Listed 2021-06-15
Face Value ₹ 10
Shares Outstanding 1,92,06,266

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VINEETLAB.md for Vineet Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month